172 related articles for article (PubMed ID: 22827244)
1. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
[TBL] [Abstract][Full Text] [Related]
2. Continuous cell lines as a production system for influenza vaccines.
Genzel Y; Reichl U
Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
[TBL] [Abstract][Full Text] [Related]
3. Developing cell culture-derived pandemic vaccines.
Barrett PN; Portsmouth D; Ehrlich HJ
Curr Opin Mol Ther; 2010 Feb; 12(1):21-30. PubMed ID: 20140813
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
Ehrlich HJ; Berezuk G; Fritsch S; Aichinger G; Singer J; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
Vaccine; 2012 Jun; 30(29):4377-86. PubMed ID: 22172502
[TBL] [Abstract][Full Text] [Related]
5. A cell-based backup to speed up pandemic influenza vaccine production.
Lee MS; Hu AY
Trends Microbiol; 2012 Mar; 20(3):103-5. PubMed ID: 22257962
[TBL] [Abstract][Full Text] [Related]
6. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
Hütter J; Rödig JV; Höper D; Seeberger PH; Reichl U; Rapp E; Lepenies B
J Immunol; 2013 Jan; 190(1):220-30. PubMed ID: 23225881
[TBL] [Abstract][Full Text] [Related]
7. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.
Chan CY; Tambyah PA
Expert Rev Vaccines; 2012 Jul; 11(7):759-73. PubMed ID: 22913252
[TBL] [Abstract][Full Text] [Related]
8. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
9. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
11. Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens.
Strecker T; Uhlendorff J; Diederich S; Lenz-Bauer C; Trusheim H; Roth B; Kolesnikova L; Aepinus C; Dornow R; Gerlach J; Matrosovich M; Valley U; Eickmann M; Becker S
Clin Chem Lab Med; 2012 May; 50(7):1275-9. PubMed ID: 22850059
[TBL] [Abstract][Full Text] [Related]
12. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
13. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
[TBL] [Abstract][Full Text] [Related]
14. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
15. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
16. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
17. [Development of a novel influenza vaccine derived from a continuous cell line].
Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
[TBL] [Abstract][Full Text] [Related]
18. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production.
Coussens PM; Smith KA; Weber PS; Colvin CJ
Vaccine; 2011 Nov; 29(47):8661-8. PubMed ID: 21911025
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
[TBL] [Abstract][Full Text] [Related]
20. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
